Constipation: Drugs That Cause It and Drugs That Treat It

Why Constipation Is So Common

Functional constipation affects an estimated 16% of adults globally and roughly 33% of adults older than 60, according to a 2020 systematic review published in the American Journal of Gastroenterology [1]. The condition generates over 2.5 million physician visits per year in the United States alone [2]. Yet a large share of these cases are partially or entirely drug-induced.

The gastrointestinal tract relies on coordinated smooth-muscle contractions, mucosal secretion, and enteric nervous system signaling to move stool forward. Any medication that disrupts one of those three mechanisms can slow transit, harden stool, or both. Identifying the offending drug is the single most efficient diagnostic step a clinician can take, because dose reduction or substitution often resolves the problem without adding another prescription [3].

Aging compounds the risk. Older adults take more medications, have less physical activity, drink less fluid, and lose enteric neurons at a rate of roughly 1% per decade after age 40 [4]. The combination creates a perfect setup for drug-induced constipation to layer on top of age-related slowing.

Medications That Cause Constipation

Opioids are the most studied offenders. They activate mu-receptors on enteric neurons, suppressing peristalsis and boosting fluid reabsorption. Opioid-induced constipation (OIC) occurs in 40% to 80% of patients on chronic opioid therapy, per a 2014 Pain Medicine review (N=16 studies) [5]. The effect is dose-dependent but does not develop tolerance the way respiratory depression does, meaning the constipation persists for as long as the opioid is taken.

Anticholinergic drugs rank second. Medications such as oxybutynin, diphenhydramine, tricyclic antidepressants (amitriptyline, nortriptyline), and first-generation antipsychotics block muscarinic M3 receptors in the gut wall, reducing both motility and secretion. A 2019 JAMA Internal Medicine cohort study (N=284,343) linked cumulative anticholinergic burden to higher rates of constipation and other adverse outcomes [6].

Calcium-channel blockers, especially verapamil, slow colonic transit by inhibiting L-type calcium channels on smooth muscle cells. Verapamil causes constipation in up to 25% of patients, a rate significantly higher than that seen with dihydropyridines like amlodipine [7].

Iron supplements (ferrous sulfate 325 mg) cause constipation in roughly 20% of users because unabsorbed iron in the colon generates reactive oxygen species that impair motility and alter the microbiome [8].

GLP-1 receptor agonists, now prescribed widely for type 2 diabetes and obesity, delay gastric emptying as part of their mechanism of action. In the STEP-1 trial (N=1,961), constipation was reported by 24.0% of participants on semaglutide 2.4 mg versus 11.1% on placebo at 68 weeks [9]. Tirzepatide shows a similar pattern. The SURMOUNT-1 trial (N=2,539) recorded constipation rates of 17.1% to 21.2% across tirzepatide dose arms compared with 4.8% for placebo [10].

Other common culprits include aluminum-containing antacids, clonidine, ondansetron, and certain chemotherapy agents such as vincristine. A practical rule: if a drug slows neural signaling, reduces secretion, or tightens smooth muscle, it can cause constipation.

How Drug-Induced Constipation Is Diagnosed

The diagnosis is clinical. Rome IV criteria define functional constipation as fewer than three spontaneous bowel movements per week, with at least two of six qualifying symptoms (straining, lumpy/hard stools, sensation of incomplete evacuation, sensation of anorectal obstruction, manual maneuvers, or reduced frequency) present for at least three months with symptom onset at least six months before diagnosis [11].

Drug-induced constipation follows a temporal pattern: symptoms start or worsen within days to weeks of initiating the offending agent and improve when the drug is discontinued or replaced. If the timeline fits, no imaging or endoscopy is needed in patients under 50 who lack alarm features. Patients with red flags (rectal bleeding, unintentional weight loss exceeding 5% in six months, iron-deficiency anemia, new onset after age 50, or family history of colorectal cancer) should undergo colonoscopy before attributing constipation to a medication [12].

The Bristol Stool Scale remains a useful bedside tool: types 1 and 2 correspond to slow transit, while types 3 and 4 are considered normal. Asking the patient to describe stool form is more reliable than asking about frequency alone, according to a 2016 Neurogastroenterology and Motility validation study [13].

First-Line Treatment: Over-the-Counter Options

PEG 3350 (polyethylene glycol, sold as MiraLAX) is the most studied osmotic laxative. A Cochrane systematic review of 10 randomized controlled trials (N=868) found PEG superior to lactulose for stool frequency and stool form, with a number needed to treat (NNT) of 3 [14]. Standard dosing is 17 g dissolved in 240 mL of water once daily. Onset typically occurs within 24 to 72 hours.

Stimulant laxatives (bisacodyl 5 to 10 mg, senna 17.2 mg) act by triggering myenteric plexus activation and increasing colonic water secretion. Contrary to a persistent myth, long-term daily use of stimulant laxatives does not damage the colon or cause dependence. The American Gastroenterological Association (AGA) 2013 position statement specifically addressed this: "There is no evidence that stimulant laxatives are harmful to the colon or result in tolerance when used at recommended doses" [15].

Fiber supplements (psyllium 5 to 10 g daily) add bulk and accelerate transit, but only when fluid intake is adequate. In patients with slow-transit constipation, fiber can worsen bloating without improving frequency. A practical approach: start PEG 3350 for four weeks, add a stimulant laxative as needed, and reassess. If the patient still has fewer than three complete spontaneous bowel movements (CSBMs) per week, escalate to prescription therapy.

Dr. Satish Rao, a gastroenterologist at Augusta University and former chair of the AGA's Motility Section, has noted: "The biggest mistake clinicians make is stopping at fiber. If PEG and a stimulant don't work within a month, the patient needs a targeted agent, not more bran" [16].

Prescription Secretagogues: Lubiprostone, Linaclotide, and Plecanatide

When over-the-counter agents fail, secretagogues are the next step. These drugs increase chloride and water secretion into the intestinal lumen, softening stool and accelerating transit.

Lubiprostone (Amitiza) activates ClC-2 chloride channels on the apical membrane of enterocytes. The FDA approved it in 2006 for chronic idiopathic constipation (CIC) at 24 mcg twice daily. In the key phase III trial (N=242), lubiprostone increased spontaneous bowel movements from a baseline of 1.4 to 5.7 per week versus 3.5 for placebo (P<0.001) [17]. The most common side effect is nausea (29%), which is reduced by taking the capsule with food.

Linaclotide (Linzess) is a guanylate cyclase-C (GC-C) agonist that increases cyclic GMP, driving chloride and bicarbonate secretion. The FDA approved it in 2012 for CIC (145 mcg) and IBS-C (290 mcg). A 12-week randomized trial (N=1,276) showed that 21.2% of linaclotide patients achieved the primary endpoint of at least three CSBMs per week (with an increase of at least one CSBM from baseline) versus 6.0% for placebo [18]. Diarrhea occurs in about 16% of patients and is the primary reason for discontinuation.

Plecanatide (Trulance), another GC-C agonist, was approved in 2017 at 3 mg once daily. Its efficacy profile is similar to linaclotide, but the rate of diarrhea may be slightly lower (about 5%) because plecanatide is pH-activated and works preferentially in the proximal colon [19].

The AGA's 2024 clinical practice update recommends linaclotide as the preferred secretagogue for CIC because of its larger evidence base and dual approval for CIC and IBS-C. Dr. Lin Chang, a professor of medicine at UCLA's Vatche and Tamar Manoukian Division of Digestive Diseases, stated in the update: "Linaclotide has the most consistent data across multiple trials and patient populations, making it our first-choice secretagogue" [20].

Prokinetics: Prucalopride

Prucalopride (Motegrity) is a selective 5-HT4 receptor agonist that stimulates high-amplitude propagating contractions in the colon. Unlike older prokinetics (cisapride, tegaserod), prucalopride has no significant cardiac effects because it does not bind hERG potassium channels.

The drug was approved in 2018 for CIC at 2 mg once daily (1 mg for patients with severe renal impairment, eGFR <30 mL/min). Three key trials (N=1,977 combined) demonstrated that 23.6% of prucalopride-treated patients achieved at least three CSBMs per week versus 11.3% on placebo over 12 weeks [21]. Headache (reported in 15% to 25% of patients) is the most common adverse event and usually resolves within the first week of treatment.

Prucalopride is a particularly useful option when the primary problem is slow transit rather than hard stool consistency. It can also be combined with a secretagogue in refractory cases, though combination therapy lacks dedicated trial data.

Treating Opioid-Induced Constipation

OIC requires a distinct approach because the mechanism is receptor-mediated and does not resolve with standard laxatives in many patients. The AGA recommends starting with PEG 3350 or a stimulant, but if these fail, peripherally acting mu-opioid receptor antagonists (PAMORAs) are indicated [22].

Naloxegol (Movantik), an oral PEGylated derivative of naloxone, was approved in 2014 at 25 mg once daily. In the KODIAC-04 trial (N=652), 44.4% of naloxegol patients responded versus 29.4% on placebo (P=0.001). Response was defined as at least three CSBMs per week with an increase of at least one from baseline for at least 9 of 12 weeks [23].

Methylnaltrexone (Relistor) is available as a 12 mg subcutaneous injection every other day. It is FDA-approved for OIC in patients on palliative care and for CIC in adults with chronic non-cancer pain. In a key trial (N=133), 48% of methylnaltrexone patients had a bowel movement within four hours of the first dose versus 15% on placebo [24].

Naldemedine (Symproic) offers a third oral option at 0.2 mg daily. The COMPOSE-1 and COMPOSE-2 trials (combined N=1,095) showed response rates of 47.6% for naldemedine versus 34.6% for placebo over 12 weeks [25].

PAMORAs do not cross the blood-brain barrier, so they block opioid receptors in the gut without reversing analgesia. Abdominal pain is the most common adverse effect (8% to 12%).

GLP-1 Agonist Constipation: A Growing Clinical Problem

As semaglutide and tirzepatide prescriptions have surged (over 40 million GLP-1 prescriptions were dispensed in the United States in 2024, per IQVIA data), constipation from these agents has become one of the most frequent drug side effects seen in primary care [26].

GLP-1 agonists slow gastric emptying and may reduce colonic motility through central and peripheral vagal pathways. Most patients experience the worst constipation during dose-escalation phases. Practical management includes adding PEG 3350 at the start of each dose increase, maintaining fluid intake above 2 liters per day, and using a stimulant laxative on an as-needed basis.

No PAMORA has been studied for GLP-1-induced constipation because the mechanism is not opioid-mediated. If standard OTC measures fail, linaclotide or prucalopride may be reasonable, though dedicated trial data in the GLP-1 population are not yet available.

When to Refer: Red Flags and Refractory Cases

Constipation that does not respond to at least two pharmacologic interventions over eight weeks warrants referral to a gastroenterologist. Anorectal manometry and balloon expulsion testing can identify pelvic floor dyssynergia, a condition present in up to 40% of patients with refractory constipation [27]. Biofeedback therapy for dyssynergia has a success rate of approximately 70% to 80% across multiple controlled trials, outperforming laxatives for this specific phenotype [28].

Colonic transit studies using radiopaque markers (Sitz marker test) or wireless motility capsule distinguish slow-transit constipation from normal-transit constipation. Slow-transit patients are more likely to benefit from prucalopride, while dyssynergic patients need biofeedback rather than additional laxatives.

Alarm features always override empiric treatment: rectal bleeding, iron-deficiency anemia, unintentional weight loss greater than 5%, a palpable abdominal mass, or new constipation after age 50 with no prior screening colonoscopy require endoscopic evaluation before any laxative trial.

The recommended initial workup for refractory constipation includes a complete blood count, thyroid-stimulating hormone (TSH), serum calcium, and fasting glucose to rule out hypothyroidism, hypercalcemia, and diabetes as contributing metabolic causes [29].